Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549666 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00549666: Completed Phase 1 study, sponsored by Sumitomo Pharma America.
NCT00549666 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00549666, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen
Interventions
- DRUG Placebo 40 mg
- DRUG Lurasidone 40 mg
- DRUG Ortho Tri-Cyclen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00549666 record still lists
NCT00549666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo 40 mg is the first listed.
NCT00549666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00549666 about?
NCT00549666 is a clinical study titled "A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects". A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen
What is the current status of trial NCT00549666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00549666?
The interventions under investigation include: Placebo 40 mg (DRUG), Lurasidone 40 mg (DRUG), Ortho Tri-Cyclen (DRUG).
Who is sponsoring clinical trial NCT00549666?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00549666's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia